Trials / Unknown
UnknownNCT06071923
Effect of Thyroid Disorders in Liver Diseases
Effect of Thyroid Disorders in Metabolic Fatty Liver Changes
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 140 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Aims of the Research 1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). 2. To detect hepatic risk in subclinical and clinical hypothyroidism . 3. To detect early liver disorders in thyroid disorders using fibroscan .
Detailed description
Non alcoholic fatty liver disease (NAFLD) has been a health problem of growing significance all over the world; its prevalence is increasing in both developed and developing countries ,the overall prevalence of NAFLD worldwide was estimated to be 32.4%.prevalence increased significantly over time. considering the increasing incidence of NALAD/NASH, especially in developed and developing countries, it is anticipated that cirrhosis due to these conditions may exceed other causes of cirrhosis in a near future.. Thyroid gland is involved in energy homeostasis, lipid and carbohydrate metabolism, regulation of body weight and adipogenesis. In a clinical setting, subclinical hypothyroidism has been associated with metabolic syndrome, cardiovascular mortality and disturbance of lipid metabolism. The prevalence of hypothyroidism was reported to 16.8% among patients with NAFLD/NASH. In recent years, growing body of evidence has led to speculation on the association between NAFLD/NASH and thyroid dysfunction. Therefore, understanding the pathophysiology, risk factors and new treatment options of NAFLD/NASH should be among the priorities in the field of hepatology
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Fibroscan | Scan the liver for metabolic fatty changes |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2025-01-01
- Completion
- 2025-02-01
- First posted
- 2023-10-10
- Last updated
- 2023-10-10
Source: ClinicalTrials.gov record NCT06071923. Inclusion in this directory is not an endorsement.